Lifesci Pharmaceuticals, Inc.
USPTO PatentsView assignee record - 6 granted patents across 3 technology areas, recorded in grant years 2017–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Lifesci ranks #41,422 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 3 technology areas.
- #41,422
- of 49,997 US assignees by volume
- 25th percentile
- by Innovation Score (27.9/100)
- 26.3
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R41422 · Foreign Corporation #41,422 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 6 grants
- LOWER-Q #41,422/49,997
- PHOTO-FINISH Lidds AB
- CPC-NARROW C07D · 3 areas
- INNOV-THIN 27.9/100
- CLAIMS-DENSE 26.3 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Lidds AB (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Lifesci’s 27.9 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Lifesci
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Lifesci Pharmaceutic… · this assignee 28
Lifesci Pharmaceutic… · this assignee
28 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Lifesci's Innovation Score is 27.9/100 (25th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Lifesci?
Each dot is one of Lifesci’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Lifesci’s own 26.3 claims/patent is ABOVE the 16.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Lifesci's grants concentrate
Lifesci Pharmaceuticals, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2017. By volume, Lifesci sits between Lidds AB and Lilac Cloud, Inc..
Who files at Lifesci's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Lidds AB
Lidds AB
6 patents
- Liebherr-france S…
Liebherr-france SAS
6 patents
- Lier Chemical
Lier Chemical Co., Ltd.
6 patents
- Life Long Driver
Life Long Driver, LLC
6 patents
- Lift Airborne
Lift Airborne Technologies LLC
6 patents
- Light Polymers Ho…
Light Polymers Holding
6 patents
- Light Wave Techno…
Light Wave Technology Inc.
6 patents
- Lilac Cloud
Lilac Cloud, Inc.
6 patents
- Lifesci Pharmaceu… ◀
Lifesci Pharmaceuticals, Inc.
6 patents
What this shows Lifesci holds 6 patents at rank #41,347, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Lifesci
By rank, the assignees closest to #41,347 in granted patent volume.
- Lidds AB #41,343 · 6 patents
- Liebherr-france SAS #41,344 · 6 patents
- Lier Chemical Co., Ltd. #41,345 · 6 patents
- Life Long Driver, LLC #41,346 · 6 patents
- Lift Airborne Technologies LLC #41,348 · 6 patents
- Light Polymers Holding #41,349 · 6 patents
- Light Wave Technology Inc. #41,350 · 6 patents
- Lilac Cloud, Inc. #41,351 · 6 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Lifesci's primary technology class.
Lifesci's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
28 25th percentile higher than 25% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 16.7% |
| 2018 | 1 | 16.7% |
| 2019 | 4 | 66.7% |
Which technologies does Lifesci Pharmaceuticals, Inc. patent most?
Top 3 of 3 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Lifesci Pharmaceuticals, Inc.'s patent record in context - here's where to go next.
- Lifesci Pharmaceuticals, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #41,422 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Lifesci Pharmaceuticals, Inc. against Lidds AB, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 27.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.